TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating)'s stock price was down 29.5% during trading on Wednesday . The stock traded as low as $0.12 and last traded at $0.14. Approximately 15,304 shares changed hands during trading, a decline of 77% from the average daily volume of 67,568 shares. The stock had previously closed at $0.20.
TC Biopharm Trading Up 41.8 %
The firm's 50-day moving average price is $0.13 and its 200 day moving average price is $0.18.
Get TC Biopharm alerts:Institutional Inflows and Outflows
A hedge fund recently bought a new stake in TC Biopharm stock. Nantahala Capital Management LLC purchased a new position in shares of TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 235,294 shares of the company's stock, valued at approximately $117,000.
About TC Biopharm
(Get Rating)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
Featured Articles
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
- Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.